The Quigley Corporation Comments on News Story Touting a Zinc Spray That Shortens the Common Cold
www8.techmall.com
DOYLESTOWN, Pa., Nov. 2 -- The Quigley Corporation,
manufacturers and distributors of COLD-EEZE® cold relief
products, said today that the public should wait until publication of
an accredited study by the manufacturers of Zicam before blindly
accepting the alleged results of the unpublished study.
"We have not yet had the opportunity to review the quality and
nature of the Zicam study, which was controlled by the Zicam staff at
an undisclosed location," said Guy Quigley, chairman and CEO.
"Therefore, The Quigley Corporation is unable to comment on the
efficacy and safety of Zicam's nasal product, since the study was not
conducted under strict outside independent accredited institutional
conditions as applied to Quigley's patented COLD-EEZE product."
Quigley noted the following facts:
-- COLD-EEZE is a proven therapy as confirmed in two double-
blind, placebo-controlled studies held at The Dartmouth College Cold
Clinic and The Cleveland Clinic Foundation.
-- The COLD-EEZE studies were peer reviewed and published in
The Journal of International Medical Research and The Annals of
Internal Medicine.
-- Most respected Journals embargo study results and disqualify
papers about products when their studies are widely broadcast prior to
publication. For example, The Quigley Corporation was fully aware of
the COLD-EEZE study results months before publication, but the news
was embargoed by the Journals.
-- The Quigley Corporation cannot understand the attempt to
promote a study that has never been published.
The Quigley Corporation is also responsible for the total funding of
the homeopathic proving to establish the safety of Zinc Gluconate,
which resulted in Zinc Gluconate receiving a monograph in the
Homeopathic Pharmacopoeia of the United States.
"I believe the public -- and the news media -- should use caution
until there is an opportunity to review the entire study and its ensuing
paper and determine what is fact and what is fiction in this case,"
Quigley said.
Certain statements in this press release are "forward-looking" within
the meaning of the Private Securities Litigation Reform Act of 1995
and involve known and unknown risk, uncertainties and other factors
that may cause the Company's actual results, performance or
achievements to be materially different from the results, performance
or achievements expressed or implied by the forward-looking
statement. Factors that impact such forward-looking statements
include, among others, changes in worldwide general economic
conditions, changes in interest rates, government regulations, and
worldwide competition.
The Quigley Corporation, a natural health and homeopathic drug
company, is the manufacturer of COLD-EEZE and COLD-EEZE
bubble gum. COLD-EEZE is the only zinc gluconate glycine
(ZIGG)TM lozenge proven in two double blind studies to reduce the
duration and severity of the common cold symptoms. The Quigley
Corporation is also the maker of the BODYMATETM Nutrition &
Weight Management Products.
For more information, please contact Will Chelak or Tom Healey of
Integrated Marketing Services at 609-683-9055, extensions 151 or 108.
SOURCE The Quigley Corporation
Web Site: quigleyco.com |
